Navigation Links
Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
Date:4/16/2008

us East performs scientific research on new medicines, and the production, wholesale and retail sale of medicines. For more information, visit http://www.LotusEast.com .

Safe Harbor Statement

Certain statements set forth in this press release constitute "forward-looking statements". Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

For more information, please contact:

Lotus Pharmaceuticals, Inc.

Mr. Adam Wasserman, CFO

Tel: +86-877-801-0344

Email: info@LotusEast.com

CCG Elite Investor Relations Inc.

Mr. Crocker Coulson, President

Tel: +1-646-213-1915 (New York)

Emai
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Lotus Pharmaceuticals Raises $5 Million in Private Placement
2. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
3. Lotus Blossom Consulting Announces E-Book on Infertility Treatment Financing
4. Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development
5. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
6. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
7. Barr Pharmaceuticals, Inc. Executive Bios
8. Alseres Pharmaceuticals, Inc. Raises $5 Million
9. Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation
10. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
11. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...Ind., Aug. 29 /PRNewswire/ -- Conseco Insurance Co...announced the availability of its new,indexed uni... The policy,provides upside potential with downsid...niversal life policy that offers the,opportunity f...m index,credit of 1%. Clients can customize their ...
(Date:8/29/2008)...Va., Aug. 29 /PRNewswire-USNewswire/ -- The Custom...d today the launch of the Endocrine,Daily Briefing...tigious,Endocrine Society., Endocrine Daily Brief...0 Endocrine Society members, medical professionals...betes and osteoporosis. Endocrine Daily,Briefing j...
(Date:8/29/2008)...ates disappointed that Obama failed to address the...- Speaking at the Democratic,National Convention W...ed,for a reinvigorated response to the domestic HI...Presidential nominee Barack Obama, Clinton said,"...ble global leadership in,an area in which I am dee...
(Date:8/29/2008)...ON, Aug. 29 /PRNewswire-USNewswire/ -- The followi...Campaign for Tobacco-Free Kids:, For the second t...d to,withdraw sponsorship and promotion of a conce...rnational criticism for engaging in cigarette,mark...p Morris International has been forced to withdraw...
Breaking Medicine News(10 mins):Health News:ConsecoLifeOptions Launched by Conseco Insurance Company as New Universal Life Product 2Health News:Custom Briefings Announces Launch of Endocrine Daily Briefing 2Health News:Bill Clinton and Other Leaders Call For 'Renewal of Battle Against AIDS' in the United States at Democratic Convention 2Health News:Bill Clinton and Other Leaders Call For 'Renewal of Battle Against AIDS' in the United States at Democratic Convention 3Health News:Philip Morris International Forced to Drop Another Concert Sponsorship; Philippines Health Department Applauded for Taking Action 2
...s suffering from tennis elbow ask them to alter th....// A new study evaluating the muscle firing patte... no bearing on the development of tendonitis. Res...p" on the relationship between the development of ...
...has made public its plan of enforcing a ban on smo...ices, cinemas, factories, pubs, bars and such othe... ban.// But the ban does not include outdoors or p...s in England will be required to put up visible “N...
...ey 2005-06 has revealed the extent of spousal viol... injustice meted out to unmarried women. The surve... f 30 organizations who were involved in accumulat...ment in certain categories. Fred Arnold, Vice-Pres...
... needed, especially into the possible genetic and ... in Bhopal exactly// 22 years ago that killed more... subsequent years. Despite the neurological, horm...he survivors are facing besides the genetic damage...
Other Medicine News:Health News:Tennis Elbow is Not Caused Due to Improperly Sized Tennis Racket Grip 2Health News:Tennis Elbow is Not Caused Due to Improperly Sized Tennis Racket Grip 3Health News:Children of Bhopal Gas Victims Suffer from Deformity 2Health News:Children of Bhopal Gas Victims Suffer from Deformity 3
(Date:8/26/2008)...wswire/ -- Semafore Pharmaceuticals Inc.,presented...geted Therapies,in Cancer in Washington, D.C., ann...se inhibitors that demonstrate significant antican... proprietary molecular scaffold has been developed...ign of pan-PI3 kinase inhibitors,as well as isofor...
(Date:8/26/2008)...nnovative Manufacturing - Has Potential to ..., ROCKVILLE, Md., Aug. 26 /PRNewswire-FirstCall/ ...favorable results from the second stage of,the Pha...uenza virus-like,particle (VLP) vaccine candidate....induced robust neutralizing antibody responses. No...
(Date:8/25/2008)... calls it a ,miracle, LATHAM, N.Y., Aug. 25 /PRN...ided Radiation Therapy program at Community Care P... patients using RapidArc(TM),radiotherapy technolo...dvancement that delivers a highly-precise image-gu...tment in two minutes or less., RapidArc treatment...
(Date:8/22/2008)...Newswire-FirstCall/ -- Human Genome,Sciences, Inc....leted the,enrollment and initial dosing of patient...umumab) in combination with the chemotherapy agent... in advanced non-small cell,lung cancer (NSCLC)., ...416/HGSLOGO ), "There is an urgent medical need ...
Breaking Medicine Technology:Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program 2Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program 3Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program 4Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program 5Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program 6Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology 2Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology 3Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer 2Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer 3Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer 4Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer 5National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti Aging Applications 1501 1National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti Aging Applications 1501 2Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine 28MSI 1436 29 Data from the North American Association for the Study of Obe 658 1Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine 28MSI 1436 29 Data from the North American Association for the Study of Obe 658 2Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine 28MSI 1436 29 Data from the North American Association for the Study of Obe 658 3Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine 28MSI 1436 29 Data from the North American Association for the Study of Obe 658 4Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine 28MSI 1436 29 Data from the North American Association for the Study of Obe 658 5Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine 28MSI 1436 29 Data from the North American Association for the Study of Obe 658 6Scientists discover tiny RNAs play a big role in controlling genes 4578 1Public not so sure personalized medicine 4574 1Public not so sure personalized medicine 4574 2
...primary and secondary endpoints of,study; no negat...opicitabine and ribavirin ~, CAMBRIDGE, Mass., Jun...ceuticals, Inc. today announced results from a pha...n therapy, consisting of,valopicitabine (NM283), I...epatitis C, pegylated interferon and ribavirin,com...
...07 /PRNewswire/ -- Accera, Inc.,today is presentin...Ib clinical trial of AC-1202 (Ketasyn) in Alzheime...International Conference on,Prevention of Dementia...of earlier clinical and preclinical studies, AC-12...ve the memory and,cognition of subjects of a parti...
Other Medicine Technology:Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 2Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 3Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 4Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 5Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 6Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 2Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 3Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 4
...serex Tango ophthalmic laser system provides two l...isruptor for posterior capsulotomy and iridotomy. ...ing pulsed 532 nm light. The photodisruptor laser ...ser can be easily selected and treatment by both l...
Thin and smooth jaws, designed to enter trough 3 mm incision, cross action.
Flat handle.
Angled shafts, smooth jaws, polished finish.
Medicine Products: